Replies to post #183163 on Avid Bioservices Inc (CDMO)

[rome75]

Piper needs to upgrade then it will move in the right direction

[4OurRetirement]

Biopharm, Price Target History per AnalystRatings.net as follows...



7/15/2014 Roth Capital Reiterated Rating Buy

5/16/2014 Zacks Downgrade Buy -> Hold

4/17/2014 Zacks Upgrade Neutral -> Outperform $2.10

3/11/2014 MLV & Co Boost Price Target Buy $2.50 -> $3.50

1/17/2014 JPMorgan Chase & Co. Lower Price Target $12.00 -> $9.50

8/1/2013 Zacks Downgrade Outperform -> Neutral $1.70

7/3/2013 Zacks Upgrade Neutral -> Outperform $1.60

6/28/2013 Roth Capital Lower Price Target $7.00 -> $5.00

6/3/2013 Roth Capital Boost Price Target Buy $4.00 -> $7.00

3/5/2013 Piper Jaffray Initiated Coverage Overweight $2.50

1/7/2013 Roth Capital Upgrade Neutral -> Buy $2.70

9/27/2012 MLV & Co Initiated Coverage Buy $4.50 -> $2.00

9/24/2012 Roth Capital Downgrade Buy -> Neutral $9.00 -> $0.70

9/10/2012 Roth Capital Boost Price Target $5.00 -> $9.00

9/7/2012 Roth Capital Reiterated Rating Buy $5.00

8/15/2012 Roth Capital Reiterated Rating Buy $5.00

[cjgaddy]

BioF, like 4OUR found, Roth went UP to $7 and back DOWN to $5 during 2013. Went back thru my history...

Roth Capital /Joe Pantginis - init. 7-15-10 Buy/PT=$10, CURR: Buy/$5.00 http://www.roth.com
. . .Universe (click link bottom right): http://roth.bluematrix.com/docs/pdf/BLUE.pdf
. . .7-15-14: Roth maintains PPHM PT=$5 ("remains encouraged by progress in FY14") http://tinyurl.com/nwacgev
. . .6-28-13: Roth lowers PPHM PT 7=>$5 (following PPHM's 6-27-13 PR/Bavi-Cash-Update)
. . .6-3-13: Roth raises PPHM PT 4=>$7 ("ASCOdata+FDA_ph3 agreement & visibility should represent the final potential triggers to conclude a partnership deal.") http://tinyurl.com/kkvddt2
. . .1-14-13: Roth raises PPHM PT 2.70=>$4.00 ("partnering discussions have new found life") http://tinyurl.com/a9t29lb
. . .1-7-13: Roth ups Neutral to BUY, PT 1.25=>$2.70 (after 2nd-Line NSCLC Review Upd) http://tinyurl.com/bfj7mva
. . .12-11-12: Roth ups PT $.70=>$1.25 after Cotara Ph3 design approval & 12-10-12/10Q-CC.
. . .9-24-12: Roth cuts PT $9=>$.70 after PPHM PR about 2nd-Line NSCLC trial data problems.
. . .9-10-12: Roth ups PT $5=>$9 ("highly encouraged by 2ndLine NSCLC clinical data") http://tinyurl.com/9blrqk7
. . .8-15-12: Roth adds PPHM to focus list as a Top Biotech Pick: http://tinyurl.com/9rx5bps
. . .5-21-12: Roth ups PT $3.30=>$5 ("impressed by the strong 2ndLine NSCLC clinical data") http://tinyurl.com/cnghzyv